Payment overview · 2025
General Payments
$388.92
15 reported records · 11 companies
Healthcare provider profile · identity verified
Kaveh Samani, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1720118458
Verified facts
What the public records show
CMS Open Payments records show Kaveh Samani, MD received $388.92 in general payments during 2025 across 15 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.86 | 18.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $56.26 | 14.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $55.15 | 14.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$36.20 | 9.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.88 | 9.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.59 | 7.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $25.64 | 6.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.37 | 6.5% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $23.02 | 5.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.55 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.40 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $388.92 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.86 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $56.26 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.15 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $36.20 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $34.88 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $34.88 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $25.64 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 356 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 292 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 110 |
| Gabapentin | Gabapentin | 260 | 96 |
| Furosemide | Furosemide | 245 | 101 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 153 | 59 |
| Eliquis | Apixaban | 149 | 73 |
| Losartan Potassium | Losartan Potassium | 149 | 57 |
| Nifedipine Er | Nifedipine | 146 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 128 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 118 | 54 |
| Carvedilol | Carvedilol | 115 | 58 |
| Azithromycin | Azithromycin | 114 | 81 |
| Trazodone Hcl | Trazodone Hcl | 114 | 53 |
| Lisinopril | Lisinopril | 109 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 108 | 47 |
| Mounjaro | Tirzepatide | 100 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 43 |
| Farxiga | Dapagliflozin Propanediol | 95 | 34 |
| Metformin Hcl | Metformin Hcl | 89 | 36 |
| Tramadol Hcl | Tramadol Hcl | 89 | 38 |
| Prednisone | Prednisone | 87 | 58 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 45 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 36 |
| Methocarbamol | Methocarbamol | 79 | 40 |
| Ozempic | Semaglutide | 78 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 74 | 30 |
| Potassium Chloride | Potassium Chloride | 72 | 36 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 18 |
| Jardiance | Empagliflozin | 61 | 19 |
| Spironolactone | Spironolactone | 61 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 43 |
| Levetiracetam | Levetiracetam | 56 | 26 |
| Allopurinol | Allopurinol | 55 | 21 |
| Montelukast Sodium | Montelukast Sodium | 55 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 17 |
| Lidocaine | Lidocaine | 54 | 20 |
| Omeprazole | Omeprazole | 53 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 39 |
| Famotidine | Famotidine | 49 | 24 |
| Nystatin | Nystatin | 49 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 46 | 14 |
| Fluconazole | Fluconazole | 45 | 27 |
| Alprazolam | Alprazolam | 43 | 21 |
| Clonidine Hcl | Clonidine Hcl | 43 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 14 |
| Lactulose | Lactulose | 41 | 29 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 21 |
| Hydrocortisone | Hydrocortisone | 38 | 19 |
| Sucralfate | Sucralfate | 38 | 28 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | 29 |
| Cefuroxime | Cefuroxime Axetil | 36 | 31 |
| Ibuprofen | Ibuprofen | 36 | 16 |
| Levofloxacin | Levofloxacin | 36 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 19 |
| Promethazine Hcl | Promethazine Hcl | 35 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 12 |
| Amoxicillin | Amoxicillin | 31 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Ondansetron Odt | Ondansetron | 30 | 18 |
| Simvastatin | Simvastatin | 29 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Torsemide | Torsemide | 28 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Ezetimibe | Ezetimibe | 23 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 14 |
| Valsartan | Valsartan | 22 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | 15 |
| Nitroglycerin | Nitroglycerin | 21 | 11 |
| Sertraline Hcl | Sertraline Hcl | 21 | 13 |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | 15 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 13 |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | 12 |
| Betamethasone Valerate | Betamethasone Valerate | 15 | 12 |
| Celecoxib | Celecoxib | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Temazepam | Temazepam | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | 13 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 11 |
| Risperidone | Risperidone | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $388.92 · 15 records | Bayer Healthcare Pharmaceuticals Inc. | Dexcom G6 Transmitter, FARXIGA, Fabhalta, IBSRELA, KRYSTEXXA, Kerendia, MINIMED 780G, TRELEGY ELLIPTA, Vafseo, Vanrafia, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error